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Cisplatin �CP�� possesses wide spectrum of antitu-
mor action and is effectively used for therapy of patients 
with ovarian cancer�� malignant tumors of testis and for 
com�ined chemotherapy of lung cancer and other solid 
tumors. However�� clinical use of CP is limited �y its sig-
nificant systemic toxicity and requires an application of 
modern means of detoxification therapy [1].
The main idea of present research is an elevation of 
antitumor action of CP and minimization of its toxicity 
via �inding of CP with high molecular weight protein 
of �lood plasma — al�umin. The choice of macro-
molecular system that includes CP and al�umin as 
a carrier was not occasional. Unique transport func-
tions of human serum al�umin �HSA�� and its a�ility to 
form complexes with numerous medicinal agents�� in 
particular�� anticancer ones�� are well known. Presently 
the complexes �etween HSA and methotrexate �MTX�� 
and its derivatives are generated�� and it has �een 
shown that independently on the route of administra-
tion to o�tain equal antitumor effect there are required 
4-5 fold higher doses of nonconjugated MTX than 
these of MTX-HSA complexes [�]. The differences 
�etween antitumor activity of nonconjugated MTX 
and MTX �ound to HSA is determined �y the period of 
existence of the preparations in �loodstream�� and �y 
different ways of their penetration into the cells: �4 h 
after administration of nonconjugated MTX and MTX-
HSA complex to the rats �earing Walker’s carcinoma�� 
nearly 1�% of the introduced dose of MTX-HSA and 
only �.�5% of nonconjugated MTX was detected in 
�lood plasma�� whilst tumor tissue accumulated ap-
proximately 14% of complex and �.�4% of noncon-
jugated MTX [�]. In experiments in vitro�� the different 
kinetics of accumulation in the cells of tritium-la�eled 
MTX and MTX-HSA was demonstrated. In contrary�� 
incorporation of 1�5I-MTX-HSA and 1�5I-HSA was charac-
terized �y similar kinetics [4]. These facts evidence 
that MTX �ound to HSA contrary to nonconjugated 
agent is penetrating the cells �y endocytosis. In all 
experimental studies�� the use of MTX-HSA complexes 
leads to decrease of toxic effects that are taking place 
upon the use of nonconjugated MTX [��� �].
In experimental studies carried on malignant cell 
lines�� tumor-�earing animals and in clinical trials it has 
�een shown that al�umin is accumulated in sufficient 
amount and meta�olized �y malignant cells. In patients 
with �ronchogenous adenocarcinoma the content of 
al�umin la�eled �y indium-111 was �.�-5.4-fold higher 
in tumor tissue than in surrounding ones [5]. HSA add-
ed to culture medium was tightly �ound �y murine and 
human cells and could �e removed only after treatment 
with enzymes or �y culturing in al�umin-free culture 
medium for period more than � days [��]. The authors 
have isolated al�umin-�inding protein with molecular 
weight of 1� k� that is expressed �y tumor cells. 
Presently there is o�tained some clinical evidence 
that not only CP�� �ut CP �ound to al�umin possesses 
antitumor activity [�]. The fact that patients with hy-
poal�uminemia reveal lower sensitivity for action of 
CP�� serves as indirect evidence on the role of CP-HSA 
�inding in appearance of antitumor activity of the com-
plex [�]. One should note that in patients with malig-
nant tumors�� al�umin is ligand-hyperloaded�� causing 
decreased ligand-�inding capacity of HSA [9�� 1�].
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So�� the a�ovemmentioned results allow to suppose 
that al�umin possesses the properties which allow to 
consider it as a perspective carrier for CP. The use 
of CP as a component of macromolecular complex 
on the �ase of al�umin make it possi�le to increase 
antitumor effect of the cytostatic and to decrease its 
toxicity. That’s why the main tasks of the research are 
the study of HSA-CP interactions�� search for means to 
increase complex-forming capacity of HSA in relation 
to CP�� and comparative analysis of antitumor activity 
and toxicity of CP and CP-HSA complex.
maTerials and meThods
In the study the next reagents were used: sodium 
octanoate�� myristinic acid �Sigma�� USA���� phenol 
red�� salicylic acid �Reanal�� Hungary���� fat-free HSA 
�Sigma�� USA���� officinal HSA �Biopharm�� Ukraine���� 
cisplatin �Veropharm�� Russia��. Reagents were of 
“superpure”grade. 
Thermograms of melting of al�umin preparations 
were done on differential adia�atic scanning micro-
calorimeter �АSМ-4 �Biopri�or�� Russia��. 
Thermal effects of complex formation �etween 
al�umin and marker ligands were registered on flow 
microcalorimeter ТАМ-���� �LKB�� Sweden��. Work-
ing concentration of al�umin was 5 mg/ml in �.�5 М 
phosphate �uffer solution�� pH = �.15. 
Conditions for �inding of CP to HSA were selected 
according to the la�oratory data [11]. To determine the 
part of al�umin-�ound CP�� the method of ultrafiltration 
was used �QTY mem�ranes�� 1PKG�� Millipore�� USA��.
For purification of officinal solution of al�umin�� 
car�on sor�ents of HSG� mark with power density 
of �.�9� g/cm� and total volume of sorption pores of 
�.� g/ cm� �IEPOR NAS of Ukraine�� were used.
Antitumor and toxic activities of CP and CP-dHSA 
complex were studied on in�red white rats weighting 
��� ± �� g �earing transplanted Guerin carcinoma. 
Animals were o�tained from the vivarium of R.E. Ka-
vetsky Institute of Experimental Pathology�� Oncology 
and Radio�iology�� NAS of Ukraine �Kyiv�� Ukraine��. All 
animal procedures were carried out under the rules of 
Ethic Committee. 
Tumor-�earing animals were housed in 4 experi-
mental groups: in groups 1 and � animals were injected 
in the tail vein with CP at the dose of �.� mg/kg of �ody 
weight �n = 1���� or CP-dHSA �n = 15�� in an equivalent 
platinum dose at each �nd day for � weeks starting 
from the day 5th after GC cells transplantation�� when 
the volume of tumor reached �.54 ± �.�� and �.5�� ± 
�.1� cm��� respectively. The animals from groups � and 
4 received dHSA �n = 15�� or physiologic solution �n = 
15�� �y the same scheme. In the �eginning of treatment 
tumor volume reached �.5� ± �.�� and �.49 ± �.1� cm� 
respectively. Intact rats �n = ���� served as the control 
group. Tumors size was determined �y three orthogo-
nal diameter’ �a�� ��� c�� according to Schrek’s formula: 
V = �a x � x c�� x �.5�. Coefficient K�� presenting the ratio 
�etween tumor volume at the given moment and initial 
tumor volume �at the �eginning of administration of 
preparation�� was used as an index characterizing the 
dynamics of tumor growth. Antitumor effect of CP in a 
complex with dHSA compared to that of CP was evalu-
ated as tumor growth inhi�ition ratio �TGIR��:
              VCP � VCP-dHSATGIR = ——————— x 1��
                        VCP
where VCP and VCP-dHSA are the volumes of tumors 
upon administration of non-�ound CP and CP in 
a complex with dHSA�� respectively.
In � days after the last injection �lood was taken 
from vena cava inferior under ether narcosis.
Content of creatinine in �lood plasma was deter-
mined �y the method of Popper [1�]. 
To evaluate “meta�olic intoxication”�� the pool of com-
pounds of low- and medium molecular weight �CLMMW�� 
of �lood plasma and erythrocytes was analyzed �y the 
method �ased on the registration of spectral characteris-
tics ������1� nm�� of aqueous solutions of supernatants 
o�tained �y sedimentation of high molecular weight 
proteins of �lood plasma and erythrocytes with 15% TCA 
solution [1�]. CLMMW pool was calculated as an area 
�etween the curve of extinction values and a�scissa axis�� 
and expressed in relative units.
Intensity of oxidative modification of proteins of 
�lood plasma was evaluated �y the method �ased on 
the reaction �etween car�oxylic derivatives of protein 
with ���4-dinitrophenylhydrazine ����4-�NP-hydrazine�� 
with the generation of sta�le derivatives of dinitro-
phenylhydrazone�� optical density of which was regis-
tered at the wave length of ��� nm [14]. The content 
of car�oxylic derivatives of proteins in �lood plasma 
was counted using the coefficient of molar a�sorption 
that is equal to �1 ��� М-1cm-1 for �NP-derivatives at 
the wave length of ��� nm.
Concentration of platinum in the samples was de-
termined using atomic a�sorptional spectrophotom-
eter С-115М1 �Ukraine�� at the wave length of ���5.9 nm 
and standard platinum solution �Fluka�� Switzerland��.
resulTs and discussion
The first task was to examine complex-forming a�ility 
of HSA toward CP and to study the possi�ility to increase 
this index via sorptional activation of the protein.
Using differential scanning microcalorimetry ap-
proach�� alterations of thermodynamic characteristics 
of fat-free HSA preparation after its interaction with 
CP were analyzed. Upon titration of HSA samples with 
CP at molar ratio of 1 : 1�� 1 : ��� 1 : ��� 1 : 5�� 1 : � and 
1 : 1��� gradual shift of high temperature maximum 
from ��1.9 ± �.� °С to ��4.� ± �.5 °С without change in 
the form of thermodynamic curve has �een shown. 
Insignificant increase of melting temperature upon the 
molar ratio of al�umin to cisplatin of 1 : 1� evidences on 
low constant of association of cytostatic with al�umin 
molecule �< 1�4 М-1��.
By the method of isothermic flow microcalori-
metry�� temperature effects of interaction of HSA-CP 
complexes o�tained at the molar ratio of al�umin to 
cisplatin of 1 : 1��� with marker ligands for second and 
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third HSA domains have �een studied. After loading 
of al�umin samples with CP�� enthalpy of �inding with 
sodium octanoate �domain III�� statistically significantly 
decreased from 19.1 ± �.� kJ/mole to 15.� ± �.� kJ/
mole. In the remaining sites insignificant decrease of 
thermal effects of reaction of interaction with phenol 
red �domain II���� salicylic and myristinic acids �domains 
II and III�� were registered; possi�ly�� it is determined �y 
cytostatic-induced conformational transition. So�� the 
second site of �inding of drugs �marker ligand — so-
dium octanoate�� located in domain III of al�umin 
molecule�� is one of the main sites for CP �inding. The 
o�tained result is of certain importance�� �ecause there 
are studies that have shown that free thiol group of 
Cys-�4 �inds only low amount of CP [9]�� and these 
that proved the presence of the other CP-�inding site 
�apart from Cys-�4�� in al�umin molecule�� the origin of 
which was not identified so far [15]. 
On the �ase of the studies carried in our �epart-
ment for many years�� it has �een shown that sorptional 
purification of officinal HSA on highly active car�on 
adsor�ents of HSG� mark allows o�tain HSA prepa-
ration free from the large part of hydropho�ic ligands 
that are present in �lood serum of the donors�� and 
from thermosta�ilizer — exactly�� sodium octanoate 
[1��]�� thus making grounds to expect some elevation 
of complex-forming a�ility of HSA toward CP�� too.
Binding of CP to HSA and dHSA has �een studied in 
�ench-top experiments �y the method of ultrafiltration. 
Upon the molar ratio of CP and officinal HSA of 1 : 1�� 
� : 1�� 5 : 1 and 1� : 1�� non-�ound part of CP yielded 
9.5�� 1�.5�� �4.5 and 4�.�%�� respectively �Fig. 1��. Upon 
mentioned CP/dHSA ratio non-�ound part of cytostatic 
was 4.���� �.��� 1�.9 та ��.4%�� respectively. 
fig. 1. Binding of cisplatin with HSA and dHSA in dependence 
on their molar ratio. The data represent the mean values of three 
separate experiments 
So�� sorptional deliganding of HSA on highly active 
car�on HSG� pyropolymers is an effective way to el-
evate its complex-forming a�ility toward cisplatin: de-
liganded HSA �inds ex tempore ���9��% of cisplatin in 
dependence  on their molar ratio�� that is 5��5% higher 
than the part of cytostatic �ound to officinal HSA.
The second task of the research was to study anti-
tumor and toxic activity of CP and CP-dHSA complex 
in the model in vivo. 
Intravenous administration of dHSA to the rats in 
the amount equal to that in CP-dHSA complex�� prac-
tically did not influence the dynamics of growth of 
Guerin’s carcinoma �Fig. ���. Starting from the day � 
after initiation of administration of CP and CP-dHSA�� 
the pronounced inhi�ition of tumor growth has �een 
o�served. Upon introduction of CP at the days ��� 9 
and 11�� the increase of tumor volume �K�� was �.5�� 4.� 
and �.� fold lower than in the case of administration of 
physiologic solution�� respectively�� whilst in the group 
of animals injected with CP-dHSA comlex this index 
was �.1�� ��.9 and 19.1 fold lower�� respectively.  TGIR 
value for CP-dHSA �compared to CP�� was 14.5�� ���.1�� 
4�.4 and �4.�% at the days 4�� ��� 9 and 11 respectively�� 
evidencing on higher inhi�itory action of cytostatic 
�ound with dHSA. After introduction of non-�ound CP 
or CP-dHSA�� regression of tumors registered during 
14 days has �een o�served in 15 and 4�% of animals�� 
respectively. Potentiation of antitumor action of CP 
after its �inding with dHSA could �e caused �y pro-
longed existence of cytostatic in �lood stream and its 
gradual accumulation in tumor tissue. Pharmacologi-
cal analysis is under way.
fig. 2. �ynamics of growth of Guerin carcinoma in rats upon 
the treatment. The data represent the averages of two separate 
experiments. К values for animals treated with CP or CP-dHSA 
were statistically different �Student’s t-test�� p < �.�5�� at days 
��� 9 and 11
High nephrotoxicity of cisplatin �due to the fact that 
excretion �y kidneys is the main route for elimination 
of CP�� is well-known negative pattern of this agent [1]. 
In �lood plasma of rats three days after termination of 
administration of non-�ound CP statistically significant 
increase of creatinine content was o�served �1��.� ± 
15.9 µM/l�� compared to intact animals ���.5 ± 1�.4 
µM/l���� whilst in animals treated with CP-dHSA this in-
dex was ��.4 ± 5.9 µM/l and didn’t differ significantly 
from its level in intact animals.
 Upon the influence of antitumor agents�� significant 
elevation of endogenous intoxication is o�served�� for 
evaluation of which the pool of compounds of low- and 
medium molecular weight �CLMMW�� in �lood plasma 
and erythrocytes of rats has �een analyzed. CLMMW 
pool in supernatants of �lood plasma increased in av-
erage �y �5�� 4��� and �5% in animals that were injected 
�y physiologic solution�� non-�ound CP and CP-dHSA 
complex respectively and compared with that in intact 
control �1�.�� ± �.� a.u.��. CLMMW pool of erythrocytes 
that yielded 59.� ± 4.� a.u. in intact animals�� was sig-
nificantly elevated only in rats treated with non-�ound 
CP ���.� ± ��.� a.u.��. In animals treated with CP-dHSA 
complex this index was equal t ���.� ± 5.�� a.u.
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It is known that intense chemotherapy promotes 
the production of reactive oxygen species caus-
ing oxidative modification of proteins of tissues and 
�lood plasma with generation of aldehyde and ketone 
derivatives [1�]. In our study�� on the �ackground on 
insignificant differences of the level of total protein�� the 
content of car�oxylic derivatives of proteins in �lood 
plasma of rats after administration of non-�ound CP 
was in average 1.5 fold higher than that in animals that 
received CP-dHSA complex �Fig. ���. At the same time 
in animals with retarded dynamics of tumor growth 
inhi�ition higher level of car�oxylic derivatives was 
o�served ��.�� and �.94 mMole/g protein���� whilst in 
animals with tumor regression — lower values ��.15 
and �.�4 mMole/g protein��. 
fig. 3. Content of car�oxylic derivatives of �lood plasma of rats: 
intact �1���� �earing GC after administration of physiologic solution 
�2���� dHSA �3���� CP �4�� and CP-dHSA �5��. The data represent the 
averages of two separate experiments
In conclusion�� the study has shown that only in 
animals that received therapy with non-�ound CP�� 
significant elevation of the level of �lood plasma creati-
nine and intensity of oxidative modification of proteins 
was registered on the �ackground of the significant 
increase of the pool of compounds of low- and medium 
molecular weight in �lood plasma and erythrocytes.
The o�tained results create the grounds to recom-
mend the use of CP in the complex with officinal 
al�umin solution�� that should �e reasona�le to purify 
prior to �inding with the use of highly active car�on 
sor�ents of HSG� mark. These procedures are not 
requiring complex technological approaches and 
could �e carried out immediately �efore administration 
of cytostatic �Fig. 4��. 
We present the formula �y which the volume of 
deliganded HSA could �e counted for preparation of 
CP-containing solution with molar ratio C : dHSA = � : 1 
�1 mg CP : �.11 g al�umin�� and 5 : 1 �1 mg CP : �.�4 g 
al�umin���� when ex tempore 95% or more than ��% of 
cytostatic is �ound: 
       �.11 ��.�4�� x � x 1�� x 1.15V = ———————————————��                                C
where V — volume of dHSA�� ml;
� — the dose of CP calculated for administration 
to patient�� mg;
С — concentration of officinal HSA�� %;
1.15 — coefficient accounting the decrease of 
al�umin concentration after sorptional purification.
fig. 4. Principal scheme for generation of CP-dHSA preparation 
for clinical use
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ИЗУЧЕНИЕ ВОЗМОЖНОСТИ ПОВЫШЕНИЯ 
ПРОТИВООПУХОЛЕВОЙ АКТИВНОСТИ И СНИЖЕНИЯ 
СИСТЕМНЫХ ТОКСИЧЕСКИХ ЭФФЕКТОВ ЦИСПЛАТИНА ПУТЕМ 
ЕГО СВЯЗЫВАНИЯ С ДЕЛИГАНДИЗИРОВАННЫМ АЛЬБУМИНОМ
Цель: оценить противоопухолевое и токсическое действие цисплатина (ЦП) в свободной форме и в комплексе с делигандизированным 
альбумином. Методы: дифференциальную сканирующую и изотермичную проточную микрокалориметрию использовали для 
исследования комплексообразования ЦП с альбумином. Для количественной оценки связанного с альбумином цитостатика 
использовали метод ультрафильтрации. Концентрацию платины в образцах определяли методом атомно-абсорбционного 
спектрального анализа. Противоопухолевый и токсический эффекты ЦП и ЦП в комплексе с делигандизированным альбумином 
изучали на крысах с карциномой Герена. Результаты: показано, что одним из основных мест связывания ЦП является второй 
лекарственный сайт, расположенный в III домене молекулы альбумина. Очистка фармакопейного сывороточного альбумина (ЧСА) на 
высокоактивных углеродных гемосорбентах марки ГСГД позволяет получить делигандизированный альбумин (дЧСА) с повышенной 
комплексообразующей способностью в отношении ЦП. ЦП в связанной с дЧСА форме обеспечивает повышение ингибирующего 
влияния цитостатика на рост карциномы Герена, при этом содержание креатинина в плазме крови повышается на 15% по сравнению 
с 40% при использовании несвязанного ЦП. Выводы: результаты проведенных исследований дают основания рекомендовать 
использование ЦП в комплексе с альбумином для усиления его противоопухолевого действия и снижения токсических эффектов.
Ключевые слова: цисплатин, человеческий сывороточный альбумин, углеродный гемосорбент ГСГД, карцинома Герена.
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